Susmita Mandal
Overview
Explore the profile of Susmita Mandal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prasad H, Bv H, Subbalakshmi A, Mandal S, Jolly M, Visweswariah S
NPJ Syst Biol Appl
. 2024 Dec;
10(1):149.
PMID: 39702657
Dysregulated pH is now recognised as a hallmark of cancer. Recent evidence has revealed that the endosomal pH regulator Na/H exchanger NHE9 is upregulated in colorectal cancer to impose a...
2.
Roy N, Lodh R, Mandal S, Jolly M, Sarma A, Bhattacharyya D, et al.
Transl Oncol
. 2024 Nov;
51:102192.
PMID: 39546955
Hepatobiliary cancers (HBCs) pose a major global health challenge, with a lack of effective targeted biomarkers. Due to their complex anatomical locations, shared risk factors, and the limitations of targeted...
3.
Sahoo S, Ramu S, Nair M, Pillai M, San Juan B, Milioli H, et al.
iScience
. 2024 Jul;
27(7):110116.
PMID: 38974967
Intra-tumoral phenotypic heterogeneity promotes tumor relapse and therapeutic resistance and remains an unsolved clinical challenge. Decoding the interconnections among different biological axes of plasticity is crucial to understand the molecular...
4.
Prasad H, Mandal S, Mathew J, Cherukunnath A, Duddu A, Banerjee M, et al.
Mol Cancer Res
. 2024 Feb;
22(5):465-481.
PMID: 38319300
Implications: Endosomal pH regulator NHE9 actively controls cytosolic Ca2+ levels to downregulate the adenylate cyclase-cAMP system, enabling colorectal cancer cells to acquire hybrid E/M characteristics and promoting metastatic progression.
5.
Sahoo S, Ramu S, Nair M, Pillai M, San Juan B, Milioli H, et al.
bioRxiv
. 2023 Oct;
PMID: 37873432
Intra-tumoral phenotypic heterogeneity promotes tumor relapse and therapeutic resistance and remains an unsolved clinical challenge. It manifests along multiple phenotypic axes and decoding the interconnections among these different axes is...
6.
Parthasarathi K, Mandal S, George J, Gaikwad K, Sasidharan S, Gundimeda S, et al.
Front Mol Biosci
. 2023 Aug;
10:1201459.
PMID: 37529379
Esophageal squamous cell carcinoma (ESCC) is the most prevalent malignant gastrointestinal tumor. Ion channels contribute to tumor growth and progression through interactions with their neighboring molecules including lipids. The dysregulation...
7.
Kar A, Medatwal N, Rajput K, Mandal S, Pani T, Khan A, et al.
Int J Cancer
. 2023 Jan;
152(11):2410-2423.
PMID: 36602287
Breast cancer (luminal and triple-negative breast cancer [TNBC]) is the most common cancer among women in India and worldwide. Altered sphingolipid levels have emerged as a common phenomenon during cancer...
8.
Muralidharan S, Sehgal M, Soundharya R, Mandal S, Majumdar S, Yeshwanth M, et al.
Curr Oncol
. 2022 Nov;
29(11):8285-8301.
PMID: 36354714
Immune evasion and metabolic reprogramming are hallmarks of cancer progression often associated with a poor prognosis and frequently present significant challenges for cancer therapies. Recent studies have highlighted the dynamic...
9.
Venkatasubramanian G, Kelkar D, Mandal S, Jolly M, Kulkarni M
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407556
Breast cancers are treated according to the ER/PR or HER2 expression and show better survival outcomes with targeted therapy. Triple-negative breast cancers (TNBCs) with a lack of expression of ER/PR...
10.
Parthasarathi K, Mandal S, Singh S, Gundimeda S, Jolly M, Pandey A, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326596
Uncontrolled growth of breast cells due to altered gene expression is a key feature of breast cancer. Alterations in the expression of ion channels lead to variations in cellular activities,...